DCB is an allosteric ligand for the metabotropic glutamate receptor mGluR-5 and displays neutral modulation. DCB does not affect agonist-stimulated mGluR-5 responses, but blocks regulation of the receptor by other allosteric modulators such as DFB
DCB is an allosteric ligand for the metabotropic glutamate receptor mGluR-5 and displays neutral modulation. DCB does not affect agonist-stimulated mGluR-5 responses, but blocks regulation of the receptor by other allosteric modulators such as DFB
DCB is an allosteric ligand for the metabotropic glutamate receptor mGluR-5 and displays neutral modulation. DCB does not affect agonist-stimulated mGluR-5 responses, but blocks regulation of the receptor by other allosteric modulators such as DFB
DCB is an allosteric ligand for the metabotropic glutamate receptor mGluR-5 and displays neutral modulation. DCB does not affect agonist-stimulated mGluR-5 responses, but blocks regulation of the receptor by other allosteric modulators such as DFB
DCB is an allosteric ligand for the metabotropic glutamate receptor mGluR-5 and displays neutral modulation. DCB does not affect agonist-stimulated mGluR-5 responses, but blocks regulation of the receptor by other allosteric modulators such as DFB
DCB is an allosteric ligand for the metabotropic glutamate receptor mGluR-5 and displays neutral modulation. DCB does not affect agonist-stimulated mGluR-5 responses, but blocks regulation of the receptor by other allosteric modulators such as DFB
BF-168, a candidate probe for PET, is found to specifically recognize both neuritic and diffuse plaques, with a K i of 6.4 nM for Aβ1-42 .In VitroBF-168, a styrylbenzoxazole derivative, is a potent agent that selectively recognizes SPs and NFTs in
BF-168, a candidate probe for PET, is found to specifically recognize both neuritic and diffuse plaques, with a K i of 6.4 nM for Aβ1-42 .In VitroBF-168, a styrylbenzoxazole derivative, is a potent agent that selectively recognizes SPs and NFTs in
BF-168, a candidate probe for PET, is found to specifically recognize both neuritic and diffuse plaques, with a K i of 6.4 nM for Aβ1-42 .In VitroBF-168, a styrylbenzoxazole derivative, is a potent agent that selectively recognizes SPs and NFTs in
BF-168, a candidate probe for PET, is found to specifically recognize both neuritic and diffuse plaques, with a K i of 6.4 nM for Aβ1-42 .In VitroBF-168, a styrylbenzoxazole derivative, is a potent agent that selectively recognizes SPs and NFTs in
BF-168, a candidate probe for PET, is found to specifically recognize both neuritic and diffuse plaques, with a K i of 6.4 nM for Aβ1-42 .In VitroBF-168, a styrylbenzoxazole derivative, is a potent agent that selectively recognizes SPs and NFTs in
BF-168, a candidate probe for PET, is found to specifically recognize both neuritic and diffuse plaques, with a K i of 6.4 nM for Aβ1-42 .In VitroBF-168, a styrylbenzoxazole derivative, is a potent agent that selectively recognizes SPs and NFTs in
BF-168, a candidate probe for PET, is found to specifically recognize both neuritic and diffuse plaques, with a K i of 6.4 nM for Aβ1-42 .In VitroBF-168, a styrylbenzoxazole derivative, is a potent agent that selectively recognizes SPs and NFTs in
BF-168, a candidate probe for PET, is found to specifically recognize both neuritic and diffuse plaques, with a K i of 6.4 nM for Aβ1-42 .In VitroBF-168, a styrylbenzoxazole derivative, is a potent agent that selectively recognizes SPs and NFTs in
BF-168, a candidate probe for PET, is found to specifically recognize both neuritic and diffuse plaques, with a K i of 6.4 nM for Aβ1-42 .In VitroBF-168, a styrylbenzoxazole derivative, is a potent agent that selectively recognizes SPs and NFTs in
BF-168, a candidate probe for PET, is found to specifically recognize both neuritic and diffuse plaques, with a K i of 6.4 nM for Aβ1-42 .In VitroBF-168, a styrylbenzoxazole derivative, is a potent agent that selectively recognizes SPs and NFTs in